NCT05916573View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

February 27, 2023

Study Completion Date

April 26, 2023

Conditions

Renal Impairment

Interventions

DRUG

HSK16149

single oral adminiatration, 20mg

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY